William Blair Estimates Pyxis Oncology Q1 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Stock analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Pyxis Oncology in a report issued on Tuesday, March 18th. William Blair analyst A. Hsieh expects that the company will earn ($0.32) per share for the quarter. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share. William Blair also issued estimates for Pyxis Oncology's Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($1.32) EPS.

Several other brokerages have also recently issued reports on PYXS. HC Wainwright reissued a "buy" rating and issued a $5.00 price objective on shares of Pyxis Oncology in a report on Wednesday, March 19th. Royal Bank of Canada restated an "outperform" rating and issued a $8.00 price objective on shares of Pyxis Oncology in a research report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $9.20.

Pyxis Oncology Stock Performance

Shares of Pyxis Oncology stock traded down $0.05 during trading on Friday, hitting $1.15. 508,048 shares of the company's stock were exchanged, compared to its average volume of 743,078. Pyxis Oncology has a 52-week low of $0.99 and a 52-week high of $6.18. The stock has a market capitalization of $70.83 million, a price-to-earnings ratio of -1.12 and a beta of 1.11. The business has a 50-day simple moving average of $1.32 and a 200-day simple moving average of $2.33.

Remove Ads

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.01. The firm had revenue of $16.15 million for the quarter.

Institutional Trading of Pyxis Oncology

Institutional investors and hedge funds have recently modified their holdings of the stock. Intech Investment Management LLC purchased a new position in shares of Pyxis Oncology in the third quarter valued at approximately $55,000. ProShare Advisors LLC acquired a new position in Pyxis Oncology in the 4th quarter valued at $26,000. MetLife Investment Management LLC lifted its holdings in Pyxis Oncology by 41.1% in the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company's stock valued at $69,000 after purchasing an additional 5,484 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in Pyxis Oncology during the 4th quarter worth $35,000. Finally, Caption Management LLC acquired a new stake in Pyxis Oncology during the 4th quarter worth $35,000. Hedge funds and other institutional investors own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.